论文部分内容阅读
目的探讨卡铂联合紫杉醇治疗宫颈癌术后淋巴结转移的临床疗效及安全性。方法选取经确诊的65例宫颈癌患者,采用卡铂联合紫杉醇同步化疗,同期选择环磷酰胺联合顺铂化疗28例、单纯放疗33例患者,观察3组的远期疗效和不良反应。结果卡铂联合紫杉醇同步放化疗3年生存率、5年生存率、局部复发率、远处转移率分别为87.69%(57/65)、76.92%(50/65)、10.77%(7/65)、13.85%(9/65),优于环磷酰胺联合顺铂同步化疗组及单纯放疗组,与单纯放疗组比较差异有统计学意义(P﹤0.05);不良反应主要为胃肠道反应、骨骼抑制与脱发,3组比较差异无统计学意义(P﹥0.05)。结论卡铂联合紫杉醇治疗宫颈癌术后淋巴结转移安全可靠,疗效显著,值得临床推广使用。
Objective To investigate the clinical efficacy and safety of carboplatin combined with paclitaxel in the treatment of postoperative lymph node metastasis of cervical cancer. Methods Sixty-five patients with cervical cancer were selected. Chemotherapy with carboplatin combined with paclitaxel was given. In the same period, 28 patients were treated with cyclophosphamide plus cisplatin, and 33 patients were treated with radiotherapy alone. The long-term efficacy and side effects of the three groups were observed. Results The 3-year survival rate, 5-year survival rate, local recurrence rate and distant metastasis rate of carboplatin combined with paclitaxel were 87.69% (57/65), 76.92% (50/65), 10.77% (7/65) ) And 13.85% (9/65) respectively, which were superior to cyclophosphamide combined with cisplatin and radiotherapy alone group (P <0.05). The main adverse reactions were gastrointestinal reaction , Skeletal inhibition and hair loss, no significant difference in the three groups (P> 0.05). Conclusion Carboplatin combined with paclitaxel in the treatment of postoperative lymph node metastasis of cervical cancer is safe and reliable, and the curative effect is significant, which is worthy of clinical promotion.